
BrainChip develops low-power edge AI chips via its Akida platform. Recent momentum reflects licensing and product roadmap optimism, but weak revenue, losses, and dilution remain risks. Technically, BRN has broken its downtrend and is testing support near 0.16 to 0.17.

4DMedical slipped to A$4.57 after its breakout rally, as traders took profit near A$5.00. Momentum remains constructive, but holding A$4.25–A$4.50 is crucial while CT expansion, acquisitions and SaaS growth support the broader story.
.webp&w=828&q=75)
Island Pharmaceuticals has regained market attention after breaking a long-term downtrend, supported by Galidesivir developments and strong trading momentum. Recent updates across biodefence, manufacturing, and intellectual property have improved sentiment, although confirmation above key resistance remains important

Regis Resources delivers record cash generation and steady production growth, reinforcing its position as a dividend‑paying, unhedged gold producer with expanding underground capacity and strong exploration momentum.
.webp&w=828&q=75)
American Tungsten & Antimony (ASX: AT4) advances its US antimony and tungsten strategy through refinery plans, exploration results and a technical breakout setup, highlighting new project developments and potential growth opportunities.

Power Minerals is drawing attention after strong Morro do Ferro rare-earth drilling, rising trading activity and a breakout above long-held resistance, while further assays and a maiden resource estimate remain key upcoming catalysts.
...